治疗复发性胶质母细胞瘤的免疫疗法的发展。
The Development of Immunotherapy for the Treatment of Recurrent Glioblastoma.
发表日期：2023 Aug 29
作者：
Xudong Liu, Zihui Zhao, Wufei Dai, Kuo Liao, Qi Sun, Dongjiang Chen, Xingxin Pan, Lishuang Feng, Ying Ding, Shiyou Wei
来源：
Cell Death & Disease
摘要：
复发性胶质母细胞瘤（rGBM）是一种高度侵袭性的脑癌，对神经肿瘤治疗构成了重大挑战，患者在复发后的生存状态通常意味着迅速恶化，因此成为导致患者死亡的主要原因。近年来，免疫疗法已经成为治疗复发性胶质母细胞瘤的有希望的策略，通过刺激体内免疫系统识别和攻击癌细胞，可以与手术、放疗和化疗等其他治疗方法结合使用，改善复发性胶质母细胞瘤患者的预后。该疗法结合了多种关键方法，如单克隆抗体的使用、嵌合抗原受体T细胞（CAR-T）疗法、检查点抑制剂、溶瘤病毒疗法、癌症疫苗以及联合策略。在本综述中，我们主要记录最新的免疫疗法以治疗胶质母细胞瘤，特别关注rGBM。
Recurrent glioblastoma (rGBM) is a highly aggressive form of brain cancer that poses a significant challenge for treatment in neuro-oncology, and the survival status of patients after relapse usually means rapid deterioration, thus becoming the leading cause of death among patients. In recent years, immunotherapy has emerged as a promising strategy for the treatment of recurrent glioblastoma by stimulating the body's immune system to recognize and attack cancer cells, which could be used in combination with other treatments such as surgery, radiation, and chemotherapy to improve outcomes for patients with recurrent glioblastoma. This therapy combines several key methods such as the use of monoclonal antibodies, chimeric antigen receptor T cell (CAR-T) therapy, checkpoint inhibitors, oncolytic viral therapy cancer vaccines, and combination strategies. In this review, we mainly document the latest immunotherapies for the treatment of glioblastoma and especially focus on rGBM.